Danish pharmaceutical giant Novo Nordisk has announced the appointment of Maziar Mike Doustdar as its new CEO, replacing Lars Fruergaard Jørgensen. The company revised financial estimates, forecasting sales growth of between 8% and 14%, below previous expectations. The statement sent shares down 23%. The revision is due to weak expectations for sales of Wegovy and Ozempic drugs in the U.S. amid increased competition and use of compounded drugs. Doustdar, with over 30 years of experience in the company, promises to focus efforts on innovation and performance.
Sources
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Bursă. Business internaţional. Scădere de 20% ieri pe acţiunile Novo Nordisk, cândva cea mai valoroasă companie europeană Grupul farmaceutic danez Novo Nordisk a anunţat marţi o revizuire în scădere a estimărilor de vânzări şi profit pentru 2025, din cauza încetinirii creşterii în Statele Unite...
Acțiunile Novo Nordisk s-au prăbușit
Latest News
08:16
ICE agent shoots Venezuelan man in Austin / Mayor calls for local investigation
08:01
Decisive meeting today at PSD. The Social Democrats are establishing their strategy regarding whether or not to support the PNL-USR-UDMR government
07:48
Germany: Far-right AfD party wins another regional election
07:39
Superliga: Dinamo – Farul Constanţa 4-0 / Dinamo returns to the top of the standings
07:24
Traian Băsescu urges Siegfried Mureșan to do a "Romanian-style deal": “Given the reputation that Sigfried Mureșan has in Brussels, within the EPP, I am convinced that if he makes a small agreement with AUR, there will be no political problem whatsoever.”
See more news